<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967226</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 4502</org_study_id>
    <secondary_id>NIH grant number 10179326</secondary_id>
    <nct_id>NCT00967226</nct_id>
  </id_info>
  <brief_title>Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas</brief_title>
  <official_title>Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nancy Bauman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemangiomas are relatively common lesions in infants. Most go away spontaneously after one
      year of life and do not need treatment. Others require treatment because they cause
      significant symptoms such as pain, or difficulty with breathing, eating or ambulating.
      Steroids have classically been used to treat hemangiomas and help to shrink them in 1/3 - 2/3
      of patients. Unfortunately, steroids have many side effects in babies so physicians have
      sought other ways to treat them. Recently, the use of propranolol, a heart medication, was
      serendipitously found to reduce the size of hemangiomas. It appears to have many fewer side
      effects than steroids but it is not yet known if it works as well as steroids. This study
      seeks to compare the effect and the side effects of propranolol versus steroids for treating
      hemangiomas that cause symptoms in infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants with symptomatic hemangiomas will be enrolled. Magnetic resonance imaging will be
      completed before starting medication if the extent of the hemangioma is not evident on
      clinical examination alone. Infants will be randomized to receive either propranolol or
      steroids for 4-6 months. Hemangioma response will be measured and compared monthly as will
      tolerability of the medications. Additionally, urine specimens will be collected at each
      visit to determine if markers are present that can predict response to therapy.

      Additionally, any hemangiomas that are excised will be examined for genetic markers to aid in
      predicting response to therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Serious adverse events with prednisolone, primarily temporary growth retardation, &lt;5th
    percentile.
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Size of Hemangioma (Length x Width) in Square mm</measure>
    <time_frame>4-5 months after initiating therapy</time_frame>
    <description>A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Medication</measure>
    <time_frame>enrollment until study close out or withdrawal up to 9 months</time_frame>
    <description>All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>enrollment until study close out or withdrawal up to 9 months</time_frame>
    <description>Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth and Development Adverse Events</measure>
    <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
    <description>Number of Growth and Development AEs in each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary/Respiratory Adverse Events</measure>
    <time_frame>enrollment through study close out or withdrawal, up to 9 months</time_frame>
    <description>Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergy/Immunology Adverse Events</measure>
    <time_frame>enrollment through study closeout or study withdrawal up to 9 months</time_frame>
    <description>Number of allergy/immunology AE per study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatologic Adverse Events</measure>
    <time_frame>enrollment to study close out or withdrawal up to 9 months</time_frame>
    <description>Number of Dermatologic Adverse Events in each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrinologic Adverse Events</measure>
    <time_frame>enrollment to close out or study withdrawal up to 9 months</time_frame>
    <description>Number of Endocrinologic AEs (of which adrenal crisis does not overlap).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Adverse Events</measure>
    <time_frame>enrollment to study withdrawal or study close out up to 9 months</time_frame>
    <description>Number of Gastrointestinal AEs in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious Adverse Events</measure>
    <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
    <description>Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic or Laboratory AEs</measure>
    <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
    <description>Number of Metabolic or Laboratory AEs in each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Adverse Events</measure>
    <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
    <description>Number of Vascular AEs in each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constitutional Adverse Events</measure>
    <time_frame>enrollment to study close out or withdrawal up to 9 months</time_frame>
    <description>Number of constitutional AEs in each study arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hemangioma of Infancy</condition>
  <arm_group>
    <arm_group_label>propranolol for treatment of hemangiomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>propranolol 0.5 mg/kg orally, 4 per day - 4-6 months</description>
    <arm_group_label>propranolol for treatment of hemangiomas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>1.0 mg/kg orally, 2 per day 4-6 months</description>
    <arm_group_label>Prednisolone</arm_group_label>
    <other_name>pediapred</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants with symptomatic hemangiomas

        Exclusion Criteria:

          -  asthma

          -  diabetes

          -  hypertension

          -  hypotension

          -  hypoglycemia

          -  liver failure

          -  previous treatment for hemangiomas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy M Bauman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute, Children's National Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pérez RS, Mora PC, Rodríguez JD, Sánchez FR, de Torres Jde L. [Treatment of infantile hemangioma with propranolol]. An Pediatr (Barc). 2010 Feb;72(2):152-4. doi: 10.1016/j.anpedi.2009.05.019. Epub 2009 Jul 23. Spanish.</citation>
    <PMID>19631595</PMID>
  </reference>
  <reference>
    <citation>Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G, Garabedian EN. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol. 2009 Aug;73(8):1168-72. doi: 10.1016/j.ijporl.2009.04.025. Epub 2009 May 29.</citation>
    <PMID>19481268</PMID>
  </reference>
  <reference>
    <citation>Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12;358(24):2649-51. doi: 10.1056/NEJMc0708819.</citation>
    <PMID>18550886</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <results_first_submitted>March 14, 2014</results_first_submitted>
  <results_first_submitted_qc>January 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2016</results_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Nancy Bauman</investigator_full_name>
    <investigator_title>Professor, George Washington University, Attending Children;s National</investigator_title>
  </responsible_party>
  <keyword>hemangioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Propranolol</title>
          <description>Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
propranolol: propranolol 0.67 mg/kg p.o. TID 4-6 months</description>
        </group>
        <group group_id="P2">
          <title>Prednisolone</title>
          <description>Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
Prednisolone: 1.0 mg/kg p.o. BID 4-6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Infants 2 weeks - 6 months of age with symptomatic, proliferating, infantile hemangiomas</population>
      <group_list>
        <group group_id="B1">
          <title>Propranolol</title>
          <description>Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
Propranolol 0.67 mg/kg p.o. TID x 4 - 6 months (2.0 mg/kg/day)</description>
        </group>
        <group group_id="B2">
          <title>Prednisolone</title>
          <description>Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
Prednisolone: 1.0 mg/kg p.o. BID x 4-6 months (2.0 mg/kg/day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="2.8" upper_limit="5.2"/>
                    <measurement group_id="B2" value="2.5" lower_limit="1.7" upper_limit="3.4"/>
                    <measurement group_id="B3" value="3.4" lower_limit="1.7" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total surface area (length x width)</title>
          <units>mm squared</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" lower_limit="1.9" upper_limit="25.6"/>
                    <measurement group_id="B2" value="3.1" lower_limit="0.8" upper_limit="10.5"/>
                    <measurement group_id="B3" value="4.2" lower_limit="0.8" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adjusted total surface area (length x width x proportion of skin involved</title>
          <units>mm squared</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" lower_limit="1.5" upper_limit="24.3"/>
                    <measurement group_id="B2" value="2.5" lower_limit="0.2" upper_limit="9.4"/>
                    <measurement group_id="B3" value="4.0" lower_limit="0.2" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ulceration</title>
          <description>(not present in all participants)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Morphology</title>
          <description>Local, Segmental, Intermediate</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segmental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depth</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>superficial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in Size of Hemangioma (Length x Width) in Square mm</title>
        <description>A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available.</description>
        <time_frame>4-5 months after initiating therapy</time_frame>
        <population>Data available at 4 or 5 months for only 9/11 propranolol participants and for 6/8 prednisolone participants due to missed appointments. Overall, 90% (138/154) study appointments were completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>A priori analysis, TSA (length x width) at baseline versus at 4 months with surrogate data at 5 months Propranolol 0.67 mg/kg p.o. TID x 4 - 6 months (2.0 mg/kg/day)</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone</title>
            <description>A priori analysis, TSA (length x width) at baseline versus at 4 months with surrogate data at 5 months
Prednisolone: 1.0 mg/kg p.o. BID x 4-6 months (2.0 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Size of Hemangioma (Length x Width) in Square mm</title>
          <description>A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available.</description>
          <population>Data available at 4 or 5 months for only 9/11 propranolol participants and for 6/8 prednisolone participants due to missed appointments. Overall, 90% (138/154) study appointments were completed.</population>
          <units>mm squared</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.34" upper_limit="0.80"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.14" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>intention to treat analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Medication</title>
        <description>All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular.</description>
        <time_frame>enrollment until study close out or withdrawal up to 9 months</time_frame>
        <population>All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. In this table &quot;Adverse Events&quot; are those exclusive of the &quot;Serious Adverse Events&quot; which are noted separately.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Number of Adverse Events in Propranolol</title>
            <description>All (total) study adverse events displayed as &quot;Adverse events&quot; including mild, moderate, and severe; as well as &quot;Serious Adverse Events&quot;</description>
          </group>
          <group group_id="O2">
            <title>Overall Number of Adverse Events in Prednisolone</title>
            <description>All (total) study adverse events displayed as &quot;Adverse events&quot; including mild, moderate, and severe; as well as &quot;Serious Adverse Events&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Medication</title>
          <description>All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular.</description>
          <population>All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. In this table &quot;Adverse Events&quot; are those exclusive of the &quot;Serious Adverse Events&quot; which are noted separately.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events (SAEs)</title>
        <description>Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.</description>
        <time_frame>enrollment until study close out or withdrawal up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Number of Serious Adverse Events in Propranolol</title>
            <description>Serious adverse events in propranolol treated participants.</description>
          </group>
          <group group_id="O2">
            <title>Number of Serious Adverse Events in Prednisolone</title>
            <description>Serious adverse events in prednisolone treated participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events (SAEs)</title>
          <description>Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.</description>
          <units>Serious Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth and Development Adverse Events</title>
        <description>Number of Growth and Development AEs in each study arm</description>
        <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Growth/Developoment AEs Propranolol</title>
            <description>Number of participants experiencing Growth/Development AEs</description>
          </group>
          <group group_id="O2">
            <title>Growth/Development AEs Prednisolone</title>
            <description>Number of participants experiencing Growth/Development AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Growth and Development Adverse Events</title>
          <description>Number of Growth and Development AEs in each study arm</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary/Respiratory Adverse Events</title>
        <description>Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm</description>
        <time_frame>enrollment through study close out or withdrawal, up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pulmonary/Respiratory AEs Propranolol</title>
            <description>Number of participants experiencing pulmonary/respiratory AEs</description>
          </group>
          <group group_id="O2">
            <title>Pulmonary/Respiratory AEs Prednisolone</title>
            <description>Number of participants experiencing pulmonary/respiratory AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary/Respiratory Adverse Events</title>
          <description>Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergy/Immunology Adverse Events</title>
        <description>Number of allergy/immunology AE per study arm</description>
        <time_frame>enrollment through study closeout or study withdrawal up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergy/Immunology Events Propranolol</title>
            <description>Adverse events in allergy/immunology in propranolol treated participants</description>
          </group>
          <group group_id="O2">
            <title>Allergy/Immunology Events Prednisolone</title>
            <description>Adverse events in allergy/immunology in prednisolone treated participants</description>
          </group>
        </group_list>
        <measure>
          <title>Allergy/Immunology Adverse Events</title>
          <description>Number of allergy/immunology AE per study arm</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatologic Adverse Events</title>
        <description>Number of Dermatologic Adverse Events in each study arm.</description>
        <time_frame>enrollment to study close out or withdrawal up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dermatologic AEs Propranolol</title>
            <description>Number of participants experiencing Dermatologic AEs</description>
          </group>
          <group group_id="O2">
            <title>Dermatologic AEs Prednisolone</title>
            <description>Number of participants experiencing Dermatologic AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatologic Adverse Events</title>
          <description>Number of Dermatologic Adverse Events in each study arm.</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endocrinologic Adverse Events</title>
        <description>Number of Endocrinologic AEs (of which adrenal crisis does not overlap).</description>
        <time_frame>enrollment to close out or study withdrawal up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endocrine AEs Propranolol</title>
            <description>Number of participants experiencing Endocrinologic AEs.</description>
          </group>
          <group group_id="O2">
            <title>Endocrinologic AEs Prednisolone</title>
            <description>Number of participants experiencing Endocrinologic AEs.</description>
          </group>
        </group_list>
        <measure>
          <title>Endocrinologic Adverse Events</title>
          <description>Number of Endocrinologic AEs (of which adrenal crisis does not overlap).</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Adverse Events</title>
        <description>Number of Gastrointestinal AEs in each arm</description>
        <time_frame>enrollment to study withdrawal or study close out up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gastrointestinal AEs Propranolol</title>
            <description>Number of Participants experiencing Gastrointestinal AEs</description>
          </group>
          <group group_id="O2">
            <title>Gastrointestinal AEs Prednisolone</title>
            <description>Number of Participants experiencing Gastrointestinal AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Adverse Events</title>
          <description>Number of Gastrointestinal AEs in each arm</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infectious Adverse Events</title>
        <description>Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever)</description>
        <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infectious AEs Propranolol</title>
            <description>Number of participants experiencing Infectious AEs</description>
          </group>
          <group group_id="O2">
            <title>Infectious AEs Prednisolone</title>
            <description>Number of participants experiencing Infectious AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Infectious Adverse Events</title>
          <description>Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever)</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic or Laboratory AEs</title>
        <description>Number of Metabolic or Laboratory AEs in each study arm.</description>
        <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metabolic/Laboratory AEs Propranolol</title>
            <description>Number of participants experiencing Metabolic or Laboratory AEs.</description>
          </group>
          <group group_id="O2">
            <title>Metabolic/Laboratory AEs Prednisolone</title>
            <description>Number of participants experiencing Metabolic or Laboratory AEs in each study arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic or Laboratory AEs</title>
          <description>Number of Metabolic or Laboratory AEs in each study arm.</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Adverse Events</title>
        <description>Number of Vascular AEs in each study arm.</description>
        <time_frame>enrollment to study withdrawal or close out up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vascular AEs Propranolol</title>
            <description>Number of participants experiencing Vascular AEs</description>
          </group>
          <group group_id="O2">
            <title>Vascular AEs Prednisolone</title>
            <description>Number of participants experiencing Vascular AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Adverse Events</title>
          <description>Number of Vascular AEs in each study arm.</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Constitutional Adverse Events</title>
        <description>Number of constitutional AEs in each study arm.</description>
        <time_frame>enrollment to study close out or withdrawal up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Constitutional AEs Propranolol</title>
            <description>Number of Participants experiencing Constitutional AEs</description>
          </group>
          <group group_id="O2">
            <title>Constitutional AEs Prednisolone</title>
            <description>Number of Participants experiencing Constitutional AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Constitutional Adverse Events</title>
          <description>Number of constitutional AEs in each study arm.</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected in first 9 months participants treated with medication.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Propranolol</title>
          <description>Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
propranolol: propranolol 0.5 mg/kg p.o. QID 6 months or less</description>
        </group>
        <group group_id="E2">
          <title>Prednisolone</title>
          <description>Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
Prednisolone: 1.0 mg/kg p.o. BID x 6 months or less</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointerstinal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constitutional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/Lab</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Growth suppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/respiratory</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Not every enrolled participant had an adverse event and some had more than one. The prednioslone participants who had adverse events warranting early withdrawal had severe failure to thrive (&lt;5th percentile), a serious adverse event.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nancy M. Bauman MD, Principle Investigator</name_or_title>
      <organization>Childrens Research Institute</organization>
      <phone>2024764270</phone>
      <email>nbauman@cnmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

